Company: VCYT
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001384101-25-000060
Chunk: 14

Company: VERACYTE, INC.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 14
---
,660,435 1,655,961 Accumulated deficit(436,936)(443,983)Accumulated other comprehensive loss(28,641)(36,090)Total stockholders’ equity1,194,936 1,175,966 Total liabilities and stockholders’ equity$1,315,411 $1,300,035  

The accompanying notes are an integral part of these condensed consolidated financial statements.

1

Table of Contents

VERACYTE, INC.

 Condensed Consolidated Statements of Operations

 (Unaudited)

 (In thousands, except share and per share amounts)

 Three Months Ended March 31, 20252024Revenue:  Testing revenue$107,309 $90,303 Product revenue3,580 3,537 Biopharmaceutical and other revenue3,584 3,004 Total revenue114,473 96,844 Cost of revenue:Cost of testing revenue28,260 25,979 Cost of product revenue1,422 2,644 Cost of biopharmaceutical and other revenue2,698 2,838 Intangible asset amortization - cost of revenue2,585 2,915 Total cost of revenue34,965 34,376 Gross profit79,508 62,468 Operating expenses:Research and development17,720 15,965 Selling and marketing24,454 23,782 General and administrative33,808 26,210 Impairment of long-lived assets— 429 Intangible asset amortization - operating expenses622 738 Total operating expenses76,604 67,124 Income (loss) from operations2,904 (4,656)Other income, net4,524 2,748 Income (loss) before income taxes7,428 (1,908)Income tax provision (benefit)381 (44)Net income (loss)$7,047 $(1,864)Earnings (loss) per share:Basic$0.09 $(0.02)Diluted$0.09 $(0.02)Shares used to compute earnings (loss) per common share:Basic78,028,254 74,759,789 Diluted80,056,024 74,759,789 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2

Table of Contents

VER